Vascular calcification in chronic kidney disease: An update

Nephrology Dialysis Transplantation

Volumn 31, Issue 1, 2016, Pages 31-39

  Schlieper, Georg ^a   Schurgers, Leon ^b   Brandenburg, Vincent ^a   Reutelingsperger, Chris ^b   Floege, Jürgen ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

cardiovascular diseases; MGP; phenotype switch; Vitamin K; VSMC

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; ANTIVITAMIN K; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM ACETATE; CALCIUM CARBONATE; CINACALCET; COLECALCIFEROL; ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE; FARNOQUINONE; FETUIN A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LANTHANUM CARBONATE; MATRIX GLA PROTEIN; OSTEOCALCIN; OSTEOPONTIN; OSTEOPROTEGERIN; PHOSPHODIESTERASE; PHYTOMENADIONE; PLACEBO; PYROPHOSPHATE; SEVELAMER; SODIUM THIOSULFATE; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; VITAMIN K GROUP; CALCIUM; PHOSPHATE;

BLOOD VESSEL CALCIFICATION; CALCIUM METABOLISM; CHONDROGENESIS; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CORONARY ARTERY CALCIFICATION; EXOSOME; EXTRACELLULAR MATRIX; HEMODIALYSIS; HUMAN; LOW DRUG DOSE; MINERALIZATION; NONHUMAN; PATHOGENESIS; PHOSPHATE METABOLISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SENESCENCE; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; CELL AGING; CHRONIC KIDNEY FAILURE; METABOLISM; PATHOLOGY; SMOOTH MUSCLE CELL; VASCULAR CALCIFICATION; VASCULAR SMOOTH MUSCLE;

ANIMALS; CALCIUM; CELL AGING; HUMANS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PHOSPHATES; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; VASCULAR CALCIFICATION;

EID: 84960157825     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv111     Document Type: Review

References (108)

1. Schlieper G, Hess K, Floege J, et al. The vulnerable patient with chronic kidney disease. Nephrol Dial Transplant 2015; doi: 10.1093/ndt/gfv041
2. Ketteler M, Schlieper G, Floege J. Calcification and cardiovascular health: new insights into an old phenomenon. Hypertension 2006; 47: 1027-1034
3. Zoccali C, London G. Con: Vascular calcification is a surrogate marker, but not the cause of ongoing vascular disease, and it is not a treatment target in chronic kidney disease. Nephrol Dial Transplant 2015; 30: 352-357
4. Finch JL, Lee DH, Liapis H, et al. Phosphate restriction significantly reduces mortality in uremic rats with established vascular calcification. Kidney Int 2013; 84: 1145-1153
5. Lanzer P, Boehm M, Sorribas V, et al. Medial vascular calcification revisited: review and perspectives. Eur Heart J 2014; 35: 1515-1525
6. Brandenburg VM, Sinha S, Specht P, et al. Calcific uraemic arteriolopathy: a rare disease with a potentially high impact on chronic kidney diseasemineral and bone disorder. Pediatr Nephrol 2014; 29: 2289-2298
7. Bover J, Evenepoel P, Urena-Torres P, et al. Pro: cardiovascular calcifications are clinically relevant. Nephrol Dial Transplant 2015; 30: 345-351
8. London G, Covic A, Goldsmith D, et al. Arterial aging and arterial disease: interplay between central hemodynamics, cardiac work, and organ flow-implications for CKD and cardiovascular disease. Kidney Int Suppl (2011) 2011; 1: 10-12
9. Tyralla K, Amann K. Cardiovascular changes in renal failure. Blood Purif 2002; 20: 462-465
10. Ketteler M, Rothe H, Kruger T, et al. Mechanisms and treatment of extraosseous calcification in chronic kidney disease.Nat RevNephrol 2011; 7: 509-516
11. O'Neill WC, Adams AL. Breast arterial calcification in chronic kidney disease: absence of smooth muscle apoptosis and osteogenic transdifferentiation. Kidney Int 2014; 85: 668-676
12. Schlieper G. Vascular calcification in chronic kidney disease: not all arteries are created equal. Kidney Int 2014; 85: 501-503
13. Schlieper G, Aretz A, Verberckmoes SC, et al. Ultrastructural analysis of vascular calcifications in uremia. J Am Soc Nephrol 2010; 21: 689-696
14. Floege J, Kim J, Ireland E, et al. Serum i PTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 2011; 26: 1948-1955
15. Derwall M, Malhotra R, Lai CS, et al. Inhibition of bone morphogenetic protein signaling reduces vascular calcification and atherosclerosis. Arterioscler Thromb Vasc Biol 2012; 32: 613-622
16. Shroff RC, McNair R, Skepper JN, et al. Chronic mineral dysregulation promotes vascular smooth muscle cell adaptation and extracellular matrix calcification. J Am Soc Nephrol 2010; 21: 103-112
17. Qi Q, Monier-Faugere MC, Geng Z, et al. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis 1995; 26: 622-631
18. Lim K, Lu TS, Molostvov G, et al. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation 2012; 125: 2243-2255
19. Scialla JJ, Lau WL, Reilly MP, et al. Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int 2013; 83: 1159-1168
20. Alam MU, Kirton JP, Wilkinson FL, et al. Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells. Cardiovasc Res 2009; 81: 260-268
21. Henley C, Davis J, Miller G, et al. The calcimimetic AMG 641 abrogates parathyroid hyperplasia, bone and vascular calcification abnormalities in uremic rats. Eur J Pharmacol 2009; 616: 306-313
22. Uitto J, Li Q, Jiang Q. Pseudoxanthoma elasticum: molecular genetics and putative pathomechanisms. J Invest Dermatol 2010; 130: 661-670
23. Pereira L, Lee SY, Gayraud B, et al. Pathogenetic sequence for aneurysm revealed in mice underexpressing fibrillin-1. Proc Natl Acad Sci USA 1999; 96: 3819-3823
24. Basalyga DM, Simionescu DT, Xiong W, et al. Elastin degradation and calcification in an abdominal aorta injury model: role of matrix metalloproteinases. Circulation 2004; 110: 3480-3487
25. Aikawa E, Aikawa M, Libby P, et al. Arterial and aortic valve calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease. Circulation 2009; 119: 1785-1794
26. Hosaka N, Mizobuchi M, Ogata H, et al. Elastin degradation accelerates phosphate-induced mineralization of vascular smooth muscle cells. Calcif Tissue Int 2009; 85: 523-529
27. Khavandgar Z, Roman H, Li J, et al. Elastin haploinsufficiency impedes the progression of arterial calcification in MGP-deficient mice. J Bone Miner Res 2014; 29: 327-337
28. Pai A, Leaf EM, El-Abbadi M, et al. Elastin degradation and vascular smooth muscle cell phenotype change precede cell loss and arterial medial calcification in a uremic mouse model of chronic kidney disease. Am J Pathol 2011; 178: 764-773
29. Lomashvili KA, Cobbs S, Hennigar RA, et al. Phosphate-induced vascular calcification: role of pyrophosphate and osteopontin. J Am Soc Nephrol 2004; 15: 1392-1401
30. St Hilaire C, Ziegler SG, Markello TC, et al. NT5E mutations and arterial calcifications. N Engl J Med 2011; 364: 432-442
31. Kiffer-Moreira T, Yadav MC, Zhu D, et al. Pharmacological inhibition of PHOSPHO1 suppresses vascular smooth muscle cell calcification. J Bone Miner Res 2013; 28: 81-91
32. Kageyama A, Matsui H, Ohta M, et al. Palmitic acid induces osteoblastic differentiation in vascular smooth muscle cells through ACSL3 and NF-kappa B, novel targets of eicosapentaenoic acid. PLoS One 2013; 8: e68197
33. Taylor J, Butcher M, Zeadin M, et al. Oxidized low-density lipoprotein promotes osteoblast differentiation in primary cultures of vascular smooth muscle cells by up-regulating Osterix expression in an Msx2-dependent manner. J Cell Biochem 2011; 112: 581-588
34. Massy ZA, Drueke TB. Vascular calcification. Curr Opin Nephrol Hypertens 2013; 22: 405-412
35. Zhou Y, Wang JY, Feng H, et al. Overexpression of c1q/tumor necrosis factor-related protein-3 promotes phosphate-induced vascular smooth muscle cell calcification both in vivo and in vitro. Arterioscler Thromb Vasc Biol 2014; 34: 1002-1010
36. Buendia P, Montes de Oca A, Madueno JA, et al. Endothelial microparticles mediate inflammation-induced vascular calcification. FASEB J 2015; 9: 73-181
37. Lee C, Bongcam-Rudloff E, Sollner C, et al. Type 3 cystatins; fetuins, kininogen and histidine-rich glycoprotein. Front Biosci (Landmark Ed) 2009; 14: 2911-2922
38. Ketteler M, Bongartz P, Westenfeld R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003; 361: 827-833
39. Schäfer C, Heiss A, Schwarz A, et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003; 112: 357-366
40. Westenfeld R, Schafer C, Kruger T, et al. Fetuin-A protects against atherosclerotic calcification in CKD. J Am Soc Nephrol 2009; 20: 1264-1274
41. Herrmann M, Schafer C, Heiss A, et al. Clearance of fetuin-A-containing calciprotein particles is mediated by scavenger receptor-A. Circ Res 2012; 111: 575-584
42. Reynolds JL, Skepper JN, McNair R, et al. Multifunctional roles for serum protein fetuin-A in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol 2005; 16: 2920-2930
43. Dautova Y, Kozlova D, Skepper JN, et al. Fetuin-A and albumin alter cytotoxic effects of calcium phosphate nanoparticles on human vascular smooth muscle cells. PLoS ONE 2014; 9: e97565
44. Demetriou M, Binkert C, Sukhu B, et al. Fetuin/alpha2-HS glycoprotein is a transforming growth factor-beta type II receptor mimic and cytokine antagonist. J Biol Chem 1996; 271: 12755-12761
45. Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997; 386: 78-81
46. Price PA, Faus SA, Williamson MK.Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 1998; 18: 1400-1407
47. Murshed M, Schinke T, McKee MD, et al. Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J Cell Biol 2004; 165: 625-630
48. Schurgers LJ, Uitto J, Reutelingsperger CP. Vitamin K-dependent carboxylation of matrix Gla-protein: a crucial switch to control ectopic mineralization. Trends Mol Med 2013; 19: 217-226
49. Kapustin AN, Davies JD, Reynolds JL, et al. Calcium regulates key components of vascular smooth muscle cell-derived matrix vesicles to enhance mineralization. Circ Res 2011; 109: e1-12
50. Hofbauer LC, Schoppet M. Osteoprotegerin: a link between osteoporosis and arterial calcification?. Lancet 2001; 358: 257-259
51. Bucay N, Sarosi I, Dunstan CR, et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12: 1260-1268
52. Kazama JJ, Shigematsu T, Yano K, et al. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis 2002; 39: 525-532
53. Okawa A, Nakamura I, Goto S, et al. Mutation in Npps in a mouse model of ossification of the posterior longitudinal ligament of the spine. Nat Genet 1998; 19: 271-273
54. Lomashvili KA, Narisawa S, Millan JL, et al.Vascular calcification is dependent on plasma levels of pyrophosphate. Kidney Int 2014; 85: 1351-1356
55. Scatena M, Liaw L, Giachelli CM. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 2007; 27: 2302-2309
56. Speer MY, McKee MD, Guldberg RE, et al. Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo. J Exp Med 2002; 196: 1047-1055
57. Giachelli CM, Speer MY, Li X, et al. Regulation of vascular calcification: roles of phosphate and osteopontin. Circ Res 2005; 96: 717-722
58. Montezano AC, Zimmerman D, Yusuf H, et al. Vascular smooth muscle cell differentiation to an osteogenic phenotype involves TRPM7 modulation by magnesium. Hypertension 2010; 56: 453-462
59. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 2004; 84: 767-801
60. Speer MY, Yang HY, Brabb T, et al. Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circ Res 2009; 104: 733-741
61. Bostrom KI, Rajamannan NM, Towler DA. The regulation of valvular and vascular sclerosis by osteogenic morphogens. Circ Res 2011; 109: 564-577
62. Byon CH, Javed A, Dai Q, et al. Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor Runx2 by AKT signaling. J Biol Chem 2008; 283: 15319-15327
63. Steitz SA, Speer MY, Curinga G, et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 2001; 89: 1147-1154
64. Gauthier-Bastien A, Ung RV, Lariviere R, et al. Vascular remodeling and media calcification increases arterial stiffness in chronic kidney disease. Clin Exp Hypertens 2014; 36: 173-180
65. Sun Y, Byon CH, Yuan K, et al. Smooth muscle cell-specific runx2 deficiency inhibits vascular calcification. Circ Res 2012; 111: 543-552
66. Iyemere VP, Proudfoot D, Weissberg PL, et al.Vascular smooth muscle cell phenotypic plasticity and the regulation of vascular calcification. J Intern Med 2006; 260: 192-210
67. Tyson KL, Reynolds JL, McNair R, et al. Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol 2003; 23: 489-494
68. Monk BA, George SJ. The effect of ageing on vascular smooth muscle cell behaviour-A mini-review. Gerontology 2015; 61: 416-426
69. Shanahan CM. Mechanisms of vascular calcification in CKD-evidence for premature ageing?. Nat Rev Nephrol 2013; 9: 661-670
70. Liu Y, Drozdov I, Shroff R, et al. Prelamin A accelerates vascular calcification via activation of the DNA damage response and senescenceassociated secretory phenotype in vascular smooth muscle cells. Circ Res 2013; 112: e99-109
71. Ragnauth CD, Warren DT, Liu Y, et al. Prelamin A acts to accelerate smooth muscle cell senescence and is a novel biomarker of human vascular aging. Circulation 2010; 121: 2200-2210
72. Shroff R, Long DA, Shanahan C. Mechanistic insights into vascular calcification in CKD. J Am Soc Nephrol 2013; 24: 179-189
73. New SE, Aikawa E. Role of extracellular vesicles in de novo mineralization: an additional novel mechanism of cardiovascular calcification. Arterioscler Thromb Vasc Biol 2013; 33: 1753-1758
74. Gyorgy B, Szabo TG, Pasztoi M, et al. Membrane vesicles, current state-of-The-Art: emerging role of extracellular vesicles. Cell Mol Life Sci 2011; 68: 2667-2688
75. Reynolds JL, Joannides AJ, Skepper JN, et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004; 15: 2857-2867
76. Proudfoot D, Skepper JN, Hegyi L, et al. Apoptosis regulates human vascular calcification in vitro: evidence for initiation of vascular calcification by apoptotic bodies. Circ Res 2000; 87: 1055-1062
77. Clarke MC, Littlewood TD, Figg N, et al. Chronic apoptosis of vascular smooth muscle cells accelerates atherosclerosis and promotes calcification and medial degeneration. Circ Res 2008; 102: 1529-1538
78. Spiegel DM, Brady K. Calcium balance in normal individuals and in patients with chronic kidney disease on low-And high-calcium diets. Kidney Int 2012; 81: 1116-1122
79. Bosticardo G, Malberti F, Basile C, et al. Optimizing the dialysate calcium concentration in bicarbonate haemodialysis. Nephrol Dial Transplant 2012; 27: 2489-2496
80. Gotch FA, Kotanko P, Thijssen S, et al. The KDIGO guideline for dialysate calcium will result in an increased incidence of calcium accumulation in hemodialysis patients. Kidney Int 2010; 78: 343-350
81. Basile C, Libutti P, Di Turo AL, et al. Effect of dialysate calcium concentrations on parathyroid hormone and calcium balance during a single dialysis session using bicarbonate hemodialysis: a crossover clinical trial. Am J Kidney Dis 2012; 59: 92-101
82. Gotch FA. Pro/Con debate: the calculation on calcium balance in dialysis lowers the dialysate calcium concentrations (pro part). Nephrol Dial Transplant 2009; 24: 2994-2996
83. Drueke TB, Touam M. Calcium balance in haemodialysis-do not lower the dialysate calcium concentration too much (con part). Nephrol Dial Transplant 2009; 24: 2990-2993
84. Messa P. The ups and downs of dialysate calcium concentration in haemodialysis patients. Nephrol Dial Transplant 2013; 28: 3-7
85. Moe SM, Drueke TB. The KDIGO guideline on dialysate calcium and patient outcomes: need for hard evidence. Kidney Int 2011; 79: 478, author reply 478-479
86. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252
87. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68: 1815-1824
88. Galassi A, Spiegel DM, Bellasi A, et al. Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders. Nephrol Dial Transplant 2006; 21: 3215-3222
89. Qunibi W, Moustafa M, Muenz LR, et al. A 1-year randomized trial of calciumacetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the CalciumAcetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008; 51: 952-965
90. Kakuta T, Tanaka R, Hyodo Tet al. Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis 2011; 57: 422-431
91. Toussaint ND, Lau KK, Polkinghorne KR, et al. Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial. Nephrology (Carlton) 2011; 16: 290-298
92. Ohtake T, Kobayashi S, Oka M, et al. Lanthanum carbonate delays progression of coronary artery calcification compared with calcium-based phosphate binders in patients on hemodialysis: a pilot study. J Cardiovasc Pharmacol Ther 2013; 18: 439-446
93. Russo D, Bellasi A, Pota A, et al. Effects of phosphorus-restricted diet and phosphate-binding therapy on outcomes in patients with chronic kidney disease. J Nephrol 2015; 28: 73-80
94. Block GA, Wheeler DC, Persky MS, et al. Effects of Phosphate Binders in Moderate CKD. J Am Soc Nephrol 2012; 23: 1407-1415
95. Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-Analysis. Lancet 2013; 382: 1268-1277
96. Delanaye P, Weekers L, Warling X, et al. Cholecalciferol in haemodialysis patients: a randomized, double-blind, proof-of-concept and safety study. Nephrol Dial Transplant 2013; 28: 1779-1786
97. Raggi P, Chertow GM, Torres PU, et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 2011; 26: 1327-1339
98. Urena-Torres PA, Floege J, Hawley CM, et al. Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study. Nephrol Dial Transplant 2013; 28: 146-152
99. Aladren Regidor MJ. Cinacalcet reduces vascular and soft tissue calcification in secondary hyperparathyroidism (SHPT) in hemodialysis patients. Clin Nephrol 2009; 71: 207-213
100. Westenfeld R, Krueger T, Schlieper G, et al. Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial. Am J Kidney Dis 2012; 59: 186-195
101. Krueger T, Schlieper G, Schurgers L, et al. Vitamin K1 to slow vascular calcification in haemodialysis patients (VitaVasK trial): a rationale and study protocol. Nephrol Dial Transplant 2014; 29: 1633-1638
102. Kruger T, Floege J. Vitamin K antagonists: beyond bleeding. Semin Dial 2014; 27: 37-41
103. Spiegel DM, Farmer B. Long-Term effects of magnesium carbonate on coronary artery calcification and bone mineral density in hemodialysis patients: a pilot study. Hemodial Int 2009; 13: 453-459
104. Mathews SJ, de Las Fuentes L, Podaralla P, et al. Effects of sodiumthiosulfate on vascular calcification in end-stage renal disease: a pilot study of feasibility, safety and efficacy. Am J Nephrol 2011; 33: 131-138
105. Toussaint ND, Lau KK, Strauss BJ, et al. Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. Am J Kidney Dis 2010; 56: 57-68
106. Moe SM, O'Neill KD, Reslerova M, et al. Natural history of vascular calcification in dialysis and transplant patients. Nephrol Dial Transplant 2004; 19: 2387-2393
107. Marechal C, Coche E, Goffin E, et al. Progression of coronary artery calcification and thoracic aorta calcification in kidney transplant recipients. Am J Kidney Dis 2012; 59: 258-269
108. Schlieper G, Brandenburg V, Ketteler M, et al. Sodium thiosulfate in the treatment of calcific uremic arteriolopathy. Nat Rev Nephrol 2009; 5: 539-543